Good Participatory Practice: Guidelines for biomedical HIV prevention trials second edition (Russian)

The Good Participatory Practice (GPP) guidelines offer trial funders, sponsors and implementers systematic guidance on how to engage stakeholders throughout the research lifecycle of HIV Prevention Trials.

This second edition of the guidelines, published in 2011, contains three sections: The Importance of Good Participatory Practice, Guiding Principles of GPP in Biomedical HIV Prevention Trials and Good Participatory Practices in Biomedical HIV Prevention Trials. The sections provide context, foundational principles and key practices.

Good Participatory Practice: Guidelines for biomedical HIV prevention trials second edition (Portuguese)

The Good Participatory Practice (GPP) guidelines offer trial funders, sponsors and implementers systematic guidance on how to engage stakeholders throughout the research lifecycle of HIV Prevention Trials.

This second edition of the guidelines, published in 2011, contains three sections: The Importance of Good Participatory Practice, Guiding Principles of GPP in Biomedical HIV Prevention Trials and Good Participatory Practices in Biomedical HIV Prevention Trials. The sections provide context, foundational principles and key practices.

Women and HIV Prevention Research: Designing, testing and marketing products to improve adherence

The fourth webinar in AVAC’s Research & Reality series, a year-long dialogue about prevention research and advocacy, this webinar provided a forum to learn about and discuss key issues around women and the HIV prevention agenda, including challenges around marketing of and adherence to new prevention options. Click for speaker details, slides and audio.

Letter to Ambassador Goosby from Kenyan Civil Society

This letter on behalf of civil society organizations working in HIV and AIDS in Kenya offers recommendations for PEPFAR’s Kenya Country Operational Plan (COP) in 2013. The letter includes calls for increased investment in HIV treatment options and enhanced participation of CSO-selected civil society groups in every stage of the COP drafting process.

Community Stakeholder Checklist

The Community Stakeholder Checklist is a set of questions that can be used by community stakeholders to evaluate a research team’s compliance with the Good Participatory Practice guidelines. The checklist can be used as a starting point for dialogue with a research team, a way to share experiences with other stakeholders or as an assessment tool.

2005 AVAC Report: AIDS Vaccines at the Crossroads

This year’s Report offers recommendations for the field in general, the Global HIV Vaccine Enterprise, policy makers, researchers and communities. Some of these recommendations will be familiar because AVAC has made them before, and they are reiterated because it is AVAC’s belief that they are still needed. The Report also provides an update on tenofovir pre-exposure prophylaxis research.

2004 AVAC Report: AIDS Vaccine Trials: Getting the Global House in Order

This year’s Report focuses on how the field is readying itself for the road ahead. Several chapters address different aspects of “readiness”—a term that means different things to different people, but that is at the heart of the AIDS vaccine advocacy agenda today.

From Research to Reality: Investing in HIV Prevention Research in a Challenging Landscape

This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. The 2013 report finds that the US government was again the biggest contributor and calls for other countries and sectors to step up to end a seven-year trend of flat funding. It also profiles growing interest in research on a therapeutic vaccines.

Investing to End the AIDS Epidemic: A New Era for HIV Prevention Research & Development

This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. The 2012 report finds increased investment by private foundations was unable to make up for the effects of the economic downturn. It also highlights the contributions to prevention research of trial participants.

Capitalizing on Scientific Progress: Investment in HIV Prevention R&D in 2010

This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. The 2011 report describes the funding environment in the wake of a number of the findings of efficacy in the RV144, CAPRISA, iPrEx and HPTN 025 trials and calls for sustained funding to build on these results.